Artikel ; Online: Glucagon secretion and its association with glycaemic control and ketogenesis during sodium-glucose cotransporter 2 inhibition by ipragliflozin in people with type 1 diabetes: Results from the multicentre, open-label, prospective study.
Diabetes, obesity & metabolism
2024 Band 26, Heft 5, Seite(n) 1605–1614
Abstract: Aim: Clinical trials showed the efficacy of sodium-glucose cotransporter 2 inhibitors for type 1 diabetes (T1D) by significant reductions in body weight and glycaemic variability, but elevated susceptibility to ketoacidosis via elevated glucagon ... ...
Abstract | Aim: Clinical trials showed the efficacy of sodium-glucose cotransporter 2 inhibitors for type 1 diabetes (T1D) by significant reductions in body weight and glycaemic variability, but elevated susceptibility to ketoacidosis via elevated glucagon secretion was a potential concern. The Suglat-AID evaluated glucagon responses and its associations with glycaemic control and ketogenesis before and after T1D treatment with the sodium-glucose cotransporter 2 inhibitor, ipragliflozin. Methods: Adults with T1D (n = 25) took 50-mg open-labelled ipragliflozin daily as adjunctive to insulin. Laboratory/clinical data including continuous glucose monitoring were collected until 12 weeks after the ipragliflozin initiation. The participants underwent a mixed-meal tolerance test (MMTT) twice [before (first MMTT) and 12 weeks after ipragliflozin treatment (second MMTT)] to evaluate responses of glucose, C-peptide, glucagon and β-hydroxybutyrate. Results: The area under the curve from fasting (0 min) to 120 min (AUC Conclusions: Ipragliflozin treatment for T1D increased postprandial glucagon secretion, which did not exacerbate postprandial hyperglycaemia but might protect against hypoglycaemia, leading to reduced glycaemic variability. The increased glucagon secretion might accelerate ketogenesis when adequate insulin is not supplied. |
---|---|
Mesh-Begriff(e) | Adult ; Humans ; 3-Hydroxybutyric Acid ; Blood Glucose ; Blood Glucose Self-Monitoring ; Diabetes Mellitus, Type 1/complications ; Diabetes Mellitus, Type 1/drug therapy ; Glucagon/metabolism ; Glucose ; Glucosides ; Glycemic Control ; Hypoglycemic Agents/therapeutic use ; Hypoglycemic Agents/pharmacology ; Insulin/therapeutic use ; Prospective Studies ; Thiophenes |
Chemische Substanzen | 3-Hydroxybutyric Acid (TZP1275679) ; Blood Glucose ; Glucagon (9007-92-5) ; Glucose (IY9XDZ35W2) ; Glucosides ; Hypoglycemic Agents ; Insulin ; ipragliflozin (3N2N8OOR7X) ; Thiophenes |
Sprache | Englisch |
Erscheinungsdatum | 2024-01-22 |
Erscheinungsland | England |
Dokumenttyp | Multicenter Study ; Journal Article |
ZDB-ID | 1454944-x |
ISSN | 1463-1326 ; 1462-8902 |
ISSN (online) | 1463-1326 |
ISSN | 1462-8902 |
DOI | 10.1111/dom.15458 |
Datenquelle | MEDical Literature Analysis and Retrieval System OnLINE |
Volltext online
Zusatzmaterialien
Kategorien
Verfügbar in ZB MED Köln/Königswinter
Zs.A 5442: Hefte anzeigen | Standort: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (2.OG) ab Jg. 2022: Lesesaal (EG) |
Über subito bestellen
Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.